US Patent

US12357711 — PSMA binding dual mode radiotracer and therapeutic

Composition of Matter · Assigned to Technische Universitaet Muenchen Klinikum Rechts Der Isar · Expires 2038-11-22 · 13y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a compound according to formula (V) or a pharmaceutically acceptable salt thereof, optionally containing a chelated radioactive cation and 18 F.

USPTO Abstract

The present invention relates to a compound according to formula (V): or a pharmaceutically acceptable salt thereof, optionally containing a chelated radioactive cation and wherein F is optionally 18 F.

Drugs covered by this patent

Posluma (FLOTUFOLASTAT F-18 GALLIUM) · Blue Earth

Patent Metadata

Patent number: US12357711
Jurisdiction: US
Classification: Composition of Matter
Expires: 2038-11-22
Drug substance claim: Yes
Drug product claim: No
Assignee: Technische Universitaet Muenchen Klinikum Rechts Der Isar
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.